Observational study on patients with hypertrophic cardiomyopathy
Observational Study for Patients With Hypertrophic Cardiomyopathy
Guangdong Provincial People's Hospital · NCT04851652
This study is trying to see how heart scarring affects the health and future of people with hypertrophic cardiomyopathy over five years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Sex | All |
| Sponsor | Guangdong Provincial People's Hospital (other) |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT04851652 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the relationship between cardiac fibrosis and prognosis in patients diagnosed with hypertrophic cardiomyopathy (HCM). A total of 500 eligible patients will be recruited based on echocardiographic diagnosis, with a median follow-up period of 5 years. The study will evaluate various endpoints, including all-cause mortality and cardiovascular events, using data collected from questionnaires, laboratory tests, and cardiac imaging. Patients with cardiac hypertrophy from other causes will be excluded to ensure a focused analysis on HCM.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with hypertrophic cardiomyopathy through echocardiography.
Not a fit: Patients with cardiac hypertrophy due to conditions like hypertension, diabetes, or those who have undergone heart transplantation will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of cardiac fibrosis in HCM, potentially leading to improved prognostic assessments and management strategies for patients.
How similar studies have performed: While there have been studies on cardiac fibrosis and HCM, this specific observational approach focusing on prognosis and biomarkers is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with hypertrophic cardiomyopathy by medical history, physical examination and echocardiography. Exclusion Criteria: * Patients with cardiac hypertrophy caused by other factors such as hypertension, diabetes, myocardial amyloidosis, mitochondria cardiomyopathy, congenital heart disease, valvular heart disease, etc; Patients who had underwent heart transplatation; Individuals not suitable for the present study due to maligant tumor or severe trauma will be excluded.
Where this trial is running
Guangzhou, Guangdong
- Guangdong cardiovascular institute — Guangzhou, Guangdong, China (RECRUITING)
Study contacts
- Study coordinator: Cheng Huang, PhD
- Email: linfeng7822@sina.com
- Phone: 020-83827812
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: HCM - Hypertrophic Cardiomyopathy, all-cause mortality, cardiovascular death, hospitalization for heart failure